Mesenchymal stem cells (MSCs) have been found to aid in the treatment of autoimmune-related lung fibrosis. Interstitial pneumonia is the inflammation of alveoli, and affects patients with pulmonary fibrosis and other connective tissue diseases. Increased fibrosis is due to an overactive immune response--mainly cytotoxic T cells. Past therapies have tried to suppress all immune cells to lower pro-fibrotic molecules. Mesenchymal stem cells are able to selectively change the composition of T cells from cytotoxic to regulatory. Bone marrow derived stem cells interfered with overactive autoimmune processes, and promoted the repair of alveoli tissue.
Scientists from the National Institute of Allergy and Infectious Diseases have developed a gene therapy utilizing stem cells, which restores immunity to patients with SCID-X1, also referred to as “Bubble Boy” disease. This genetic disorder prevents immune cells from developing properly, leaving patients prone to potentially fatal infections.
In a newly published phase II clinical trial from the Asan Medical Center in Seoul, Korea, researchers observed full recovery from fistulas [abnormal connections between organs caused by the inflammation] in 75% of patients suffering from Crohn’s disease upon the injection of autologous [the patient’s own] stem cells. MSCs have the ability to regulate the patient’s immune system to reduce inflammation, resulting in the complete closure of the fistulas without recurrence.
Topics: large intestine, bank dental stem cells, Crohn's Disease, autologousstemcells, autoimmune disease, gastrointestinal disease, autoimmune attack, research, StemSave, mesenchymal stem cells, organs, stem cells, Fistulas